NR2F2 and melanoma: Retrospective and prospective studies will be required to determine whether NR2F2-Iso2 expression in primary melanomas could function as a prognostic marker for their metastatic dissemination and whether patients with NR2F2-Iso2 re-expression would benefit from treatment with pharmacological NR2F2 inhibitors or other adjuvant treatment approaches.